Antibe Therapeutics Short Interest Ratio and Short Volume

+0.05 (+5.15 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume81,263 shs
Average Volume40,926 shs
Market Capitalization$52.70 million
P/E RatioN/A
Dividend YieldN/A

Antibe Therapeutics (OTCMKTS:ATBPF) Short Interest Data

Current Short Volume900 shares
Previous Short Volume24,700 shares
Change Vs. Previous Month-96.36%
Dollar Volume Sold Short$900.00
Short Interest Ratio / Days to Cover0.0
Last Record DateAugust, 31 2021
Outstanding Shares51,670,000 shares
Percentage of Shares Shorted0.00%
Today's Trading Volume81,263 shares
Average Trading Volume40,926 shares
Today's Volume Vs. Average98.56%

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Antibe Therapeutics ?

Sign up to receive the latest short interest report for Antibe Therapeutics and its competitors with MarketBeat's FREE newsletter.

Antibe Therapeutics (OTCMKTS:ATBPF) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/31/2021900 shares $900.00 -96.4%N/A0 $1.00
8/13/202124,700 shares $25,935.00 -88.2%N/A0.1 $1.05
7/30/2021208,400 shares $561,638.00 +10.7%N/A6.6 $2.70
7/15/2021188,200 shares $513,409.60 -0.1%N/A9.6 $2.73
6/30/2021188,300 shares $559,251.00 -3.7%N/A5.8 $2.97
6/15/2021195,500 shares $602,218.20 -8.2%N/A5.5 $3.08
5/28/2021212,900 shares $724,924.50 +8.0%N/A11 $3.41
5/14/2021197,200 shares $646,816.00 -5.6%N/A8.2 $3.28
4/30/2021208,900 shares $714,458.89 +6.8%N/A5.8 $3.42
4/15/2021195,600 shares $708,072.00 -12.6%N/A9.5 $3.62
3/31/2021223,700 shares $883,615.00 +41.5%N/A1.8 $3.95
3/15/2021158,100 shares $623,388.30 -54.4%N/A3.2 $3.94
2/26/2021346,600 shares $1.50 million +439.9%N/A2 $4.34
2/12/202164,200 shares $301,098.00 -17.3%N/A0.5 $4.69
1/29/202177,600 shares $219,297.60 +21.1%N/A1.8 $2.83
12/31/202028,600 shares $89,518.00 No ChangeN/A0.5 $3.13
11/30/202030,700 shares $9,513.93 +332.4%N/A0.1 $0.31
11/15/20207,100 shares $2,188.93 -64.5%N/A0.1 $0.31
10/30/202020,000 shares $4,800.00 No ChangeN/A0.2 $0.24
10/15/202020,000 shares $5,342.00 +52.7%N/A0.2 $0.27
9/30/202013,100 shares $3,445.30 No ChangeN/A0 $0.26
8/31/20201,300 shares $388.96 -93.1%N/A0 $0.30
8/14/202018,900 shares $5,934.60 -44.9%N/A0 $0.31
7/31/202034,300 shares $9,569.70 +2,350.0%N/A0.1 $0.28
7/15/20201,400 shares $408.52 -92.4%N/A0 $0.29

Antibe Therapeutics (OTCMKTS:ATBPF) Short Interest FAQ

speech bubbles
speech bubbles

What is Antibe Therapeutics' current short interest?

Short interest is the volume of Antibe Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 31st, traders have sold 900 shares of ATBPF short. Learn More on Antibe Therapeutics' current short interest.

Is Antibe Therapeutics' short interest increasing or decreasing?

Antibe Therapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 900 shares, a decline of 96.4% from the previous total of 24,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Antibe Therapeutics' short interest compare to its competitors?

0.00% of Antibe Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Antibe Therapeutics: Oncternal Therapeutics, Inc. (4.51%), Decibel Therapeutics, Inc. (5.37%), FS Development Corp. II (0.04%), Gemini Therapeutics, Inc. (9.59%), Seelos Therapeutics, Inc. (5.01%), NextCure, Inc. (5.10%), Kala Pharmaceuticals, Inc. (18.63%), TFF Pharmaceuticals, Inc. (2.08%), Galera Therapeutics, Inc. (1.69%), and Sol-Gel Technologies Ltd. (1.56%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Square, Inc. ($9.81 billion), S&P Global Inc. ($7.52 billion), Advanced Micro Devices, Inc. ($7.18 billion), Charter Communications, Inc. ($6.21 billion), Wayfair Inc. ($4.60 billion), Zoom Video Communications, Inc. ($3.23 billion), Uber Technologies, Inc. ($3.11 billion), Palo Alto Networks, Inc. ($2.74 billion), Teladoc Health, Inc. ($2.52 billion), and Etsy, Inc. ($2.16 billion). View all of the most shorted stocks.

What does it mean to sell short Antibe Therapeutics stock?

Short selling ATBPF is an investing strategy that aims to generate trading profit from Antibe Therapeutics as its price is falling. Antibe Therapeutics' stock is trading up $0.05 today. To short Antibe Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Antibe Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Antibe Therapeutics?

A short squeeze for Antibe Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATBPF, which in turn drives the price of the stock up even further.

How often is Antibe Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATBPF, twice per month. The most recent reporting period available is August, 31 2021.

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.